Table 3 Logistic analysis for RA patients with severe sarcopenia.
Variables | Univariate | Multivariate | ||||||
|---|---|---|---|---|---|---|---|---|
Model 1 | Model 2 | Model 3 | ||||||
OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | |
Age (1 year) | 1.15 (1.08–1.22) | < 0.0001 | 1.17 (1.09–1.25) | < 0.0001 | 1.21 (1.10–1.33) | < 0.0001 | 1.21 (1.10–1.33) | < 0.0001 |
Body mass index (1 kg/m2) | 0.76 (0.67–0.86) | < 0.0001 | 0.72 (0.62–0.84) | < 0.0001 | 0.76 (0.60–0.95) | 0.0085 | 0.76 (0.60–0.95) | 0.010 |
Low 25(OH)D status (≦16.0 ng/ml) | 4.25 (1.99–9.09) | < 0.0001 | 4.42 (1.80–10.8) | 0.0007 | 5.92 (1.98–17.7) | 0.0006 | 6.00 (1.99–18.08) | 0.0006 |
DAS28-ESR | 1.58 (1.09–2.31) | 0.015 | 1.03 (0.62–1.74) | 0.90 | 1.23 (0.86–1.76) | 0.88 | ||
Stage (3, 4 vs. 1, 2) | 4.44 (1.74–11.4) | 0.0005 | 4.33 (1.33–14.08) | 0.0010 | 4.40 (1.35–14.32) | 0.0097 | ||
HAQ | 4.03 (2.19–7.41) | < 0.0001 | ||||||
Methotrexate use | 0.58 (0.28–1.19) | 0.14 | 2.18 (0.66–7.22) | 0.19 | 2.18 (0.66–7.22) | 0.19 | ||
Prednisolone use | 2.91 (1.39–6.11) | 0.0049 | 2.45 (0.74–8.06) | 0.09 | 2.45 (0.74–8.06) | 0.13 | ||
Biological agents use | 0.47 (0.21–1.03) | 0.058 | 0.70 (0.22–2.21) | 0.52 | 0.70 (0.22–2.21) | 0.54 | ||
MNA-SF | 0.70 (0.59–0.85) | < 0.0001 | 0.91 (0.66–1.24) | 0.54 | 0.90 (0.66–1.24) | 0.53 | ||
Osteoporosis medication (+) | 1.72 (0.82–3.59) | 0.15 | 1.22 (0.40–3.72) | 0.73 | ||||